| Name | Title | Contact Details |
|---|
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.
Lake Region Medical collaborates with the world’s leading medical device companies to deliver life-changing innovations that enhance the lives of patients. Backed by decades of experience and clinical expertise, we help customers bring products from concept to point-of-care in the Cardio & Vascular and Advanced Surgical markets. Lake Region Medical offers fully-integrated outsourced manufacturing and engineering services, contract manufacturing, finished device assembly, original device development and supply chain management services.
Hear Pod Hearing Aids is a Cornelius, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pleomorphic Product Sales is a Glendale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avita Medical is a publicly listed regenerative medicine company trading on the Australian Stock Exchange (ASX:AVH) and OTC Markets (OTCQX:AVMXY). The company`s lead product, ReCell® is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA- registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use.